Rajiv Doshi

About Rajiv Doshi

Dr. Rajiv Doshi serves as an Adjunct Professor of Medicine and as the Director of the India Program at the Byers Center for Biodesign. Dr. Doshi is also the co-Director of the India-based Founders Forum, an executive education training program for India’s leading health technology entrepreneurs. He has also advised the Government of India and various state governments in the development of policies that support Indian health technology innovation.

In 2007, Dr. Doshi co-founded and served as Executive Director (US) of the Stanford-India Biodesign program, Biodesign’s first international fellowship program. The goal of the India Biodesign Program was to train the next generation of medical technology innovators in India. Supported by the Government of India, the program represented a first-of-its-kind collaboration between Stanford University, the Indian Institute of Technology (IIT) Delhi, and the All India Institute of Medical Sciences (AIIMS). In total, the program trained 32 fellows who have commercialized over a dozen novel health technologies for India.

Dr. Doshi advises pro bono over two dozen India-based startups and serves pro bono on the Board of Directors and Investment Committee of TEAMFund, an impact investment fund focused on medical technology innovation for India and Africa. Dr. Doshi is also the Founder and CEO of Piper Biosciences, a Bay Area startup that is developing clinical nutrition products that help manage chronic medical conditions, based on medical guidelines. Dr. Doshi previously founded Ventus Medical, where he served as its first CEO. Dr. Doshi is the inventor of the core nasal EPAP technology of Ventus Medical’s products: for obstructive sleep apnea (Provent Sleep Apnea Therapy) and snoring (Theravent Snoring Therapy). Provent represented the first new class of obstructive sleep apnea therapy since CPAP. Dr. Doshi has served as a Sr. Advisor to McKinsey & Co. and as Principal at De Novo Ventures, a medical technology venture capital fund. Dr. Doshi has roughly 80 US and international patents issued or pending.